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Abstract  
 
COPD and lung cancer are major lung diseases affecting millions worldwide. Both diseases 
have links to cigarette smoking, and exert a considerable societal burden. People suffering from 
COPD are especially at a higher risk of developing lung cancer and are more susceptible to 
poor outcomes after diagnosis and treatment. Lung cancer and COPD are closely associated, 
possibly sharing common traits such as an underlying genetic predisposition, epithelial and 
endothelial cell plasticity, dysfunctional inflammatory mechanisms including the deposition of 
excessive extracellular matrix, angiogenesis and susceptibility to DNA damage and cellular 
mutagenesis. In fact, COPD could indeed be the driving factor for lung cancer, providing a 
conducive environment that propagates its evolution. In the early stages of smoking, the body’s 
defences provide a combative immune/oxidative response and DNA repair mechanisms are 
likely to subdue these changes to a certain extent; however, in patients with COPD with lung 
cancer the consequences could be devastating, potentially contributing to slower post-operative 
recovery after lung resection and increased resistance to radio and chemotherapy. Vital to the 
development of new-targeted therapies is an in-depth understanding of the various molecular 
mechanisms that are associated with both pathologies. Thus in this comprehensive review, we 
shall provide a detailed overview of the possible underlying factors that link COPD and lung 
cancer and current therapeutic advances both from both human and pre-clinical animal models 
that can effectively mitigate this unholy relationship. 
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Key points –  
 
There is consistent evidence that COPD and lung cancer share common pathological 
mechanisms but more understanding is needed. Only by understanding what is happening new 
therapeutic targets may emerge.   
 
Since 90% of the cancers in human body are of epithelial origin, therefore it is quite possible 
that epithelial mesenchymal transition (EMT) is the potential link between COPD and lung 
cancer and is further exaggerated by associated pathologies such as angiogenesis, oxidative 
stress and inflammation.  
 
Inhaled corticosteroids suppress EMT in COPD patients and decrease lung cancer risk as 
shown in epidemiological studies. EMT might be the process through which inhaled 
corticosteroids are showing anti-cancer effects. This suggests EMT as a novel therapeutic target 
for management of both COPD and lung cancer.  
 
Majority of the lung cancer and obliteration of small airways occurs quite early in COPD. 
Therefore, it is important to understand mechanism that gets switched on early in the disease, 
to have more personalised early intervention.  
 
Exercise training should be part of the multidisciplinary management of patients with both 
COPD and lung cancer.  
 
1. COPD and lung cancer  
 
Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory condition 
associated with several comorbidities, including lung cancer. Compared to smokers without 
COPD, people with COPD are twice as likely to develop lung cancer, a common cause of death 
in COPD [1]. Further, patients with lung cancer and concomitant COPD have a worse survival 
than patients with lung cancer without COPD [2-4]. Although association between both of 
these diseases has been established for decades, therapeutic approaches for preventing lung 
cancer in patients with COPD remain limited. Co-existing COPD may limit treatment options 
for lung cancers and thus must be assessed and managed in a timely manner. Lung cancer is 
now considered one of the most common forms of cancer in the world, with 1.8 million new 
cases detected annually (as of 2015) and 1.6 million deaths worldwide [5]. The current average 
survival rate for lung cancer patients is 5 years in population that varies from 4-17% depending 
on regional differences and this has been attributed to the poor advances in treatment and 
diagnostics [5, 6]. Worldwide, smoking prevalence has steadily increased and is currently the 
major contributor, with about 80% of lung cancer related deaths linked to smoking in the 
United States (US) and France [7], 61% in Asia, and 40% in sub-Saharan Africa. Other causes 
of lung cancer also includes second hand tobacco smoking, and with over 21,400 lung cancer 
deaths in non-smokers annually [8]. In lower and middle-income countries the risks for lung 
cancer are also associated with indoor air pollution mostly due to combustion of wood or coal 
used for cooking and heating purpose [9]. A recent estimate by Australian Institute of Health 
and Welfare (AIHW) [10] found that lung cancer was the leading cause of death for both male 
and female Australians followed by colorectal, breast, prostrate, and pancreatic cancer. In 2017, 
nearly 12,500 Australians were diagnosed with lung cancer, which is 34 people every day [10]. 
Lung cancer also remained the highest in overall burden among different cancers [10]. 
 
Lung cancer are broadly classified into two major types; non-small-cell lung cancer (NSCLC) 
and small-cell lung cancer (SCLC) [11, 12]. NSCLC constitute 85% of all lung cancers, and is 
further characterised into squamous cell carcinoma (SqCC), adenocarcinoma, and large cell 
carcinoma. SqCC  is the most common form of NSCLC, and accounts for up to 30% of all lung 
cancers [13]. While SqCC typically arises from large airway bronchial squamous epithelium, 
adenocarcinoma arises from the secretory (glandular) cells that are located in the distal 
epithelium lining of the lung bronchi [14]. Although adenocarcinoma is most often found in 
smokers, it is also the more prevalent variant of NSCLC in non-smokers. Large-cell carcinoma 
consists of large-sized cells that are anaplastic and arises from large airways [15]. In addition 
to these common subtypes of NSCLC, there are also other variants, including bronchoalveolar 
carcinoma, mixed and undifferentiated pulmonary carcinomas.  
 
Small-cell lung cancer (SCLC) usually arises centrally in the chest (large airways or lymph 
nodes) [16]. It is associated with paraneoplastic syndromes at presentation such as 
inappropriate secretion in antidiuretic hormone as small-cell tumours contain dense 
neurosecretory granules that can then give this tumour endocrine/paraneoplastic syndrome 
components. SCLCs have traditionally been staged into limited and extensive stage disease 
[17]. They are divided into typical and atypical and can grow either in the airways or in the 
lung periphery [16, 17]. Like SCLC, carcinoid tumours are characterised as neuroendocrine 
tumours, which are commonly located in the gastrointestinal tract,  and occasionally in the lung 
[18].  
 
 
 
2. Chemoprevention for lung cancer in COPD 
 
To date, smoking cessation is the only proven effective approach for preventing lung cancer in 
patients with COPD [19-21]. In view of potential shared mechanism of chronic inflammation 
in both diseases, chemoprotective effect of anti-inflammatory agents in COPD population has 
been assessed. Three retrospective studies of patients with COPD from different countries 
found a reduced risk of lung cancer in those using inhaled corticosteroids [22-24]; Table 1), 
with a negative dose-response relationship between the dose of inhaled corticosteroids and the 
risk of developing lung cancer [22-24]. A meta-analysis of seven randomized controlled trials 
assessing the effects of inhaled corticosteroids in COPD (n = 5085) revealed a trend towards 
decreased lung cancer mortality in the treatment group compared to the placebo group [25]. In 
contrast, inhaled corticosteroids have not been shown to exert significant chemopreventive 
effects in smokers with premalignant lung lesions [26, 27]. The exact mechanisms through 
which inhaled corticosteroids exert these anti-cancer effects are not clear, however, we will 
discuss potential mechanisms later in this review.  
 
Statins have also been shown to have a possible role in preventing lung cancer [28]. A 
retrospective cohort study of more than 40,000 patients with COPD reported that the use of 
statins reduced lung cancer risk by 63% [29]. However, neither inhaled corticosteroids nor 
statins have been evaluated in prospective controlled trials. Given the lack of definitive 
evidence, neither agent should be used solely for their potential chemoprotective effects in 
patients with COPD. Chemoprevention for lung cancer has also been investigated in ever-
smokers who may have COPD. Pre-clinical and epidemiologic studies indicated potential 
protective roles of antioxidants in preventing cancers [30].  However, randomised controlled 
trials on lung cancer prevention using antioxidant supplements in ever-smokers have been 
disappointing. Neither individual or combination supplementation of alpha-tocopherol, beta-
carotene and retinol was found to reduce lung cancer risk in major randomised controlled trials, 
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention study (ATBC) [31] and Beta-
Carotene and Retinol Efficacy trial (CARET)[32]. Indeed, the ATBC and CARET studies, 
which include over 47,000 ever-smokers in total, have consistently shown an increased risk of 
lung cancer with beta-carotene supplementation in ever-smokers [31, 32]. A recent prospective 
cohort study of vitamin B supplementation for lung cancer found that high-dose vitamin B6 or 
B12 supplementation increased lung cancer risk in male smokers [33]. The mechanism of 
increased lung cancer risk with micronutrient supplementations is unclear.  
 
3. Impact of COPD and lung cancer on exercise capacity 
 
Exercise capacity in patients with chronic respiratory diseases such as COPD and/or lung 
cancer is impaired and often limited by symptoms such as dyspnoea and leg fatigue [34]. In 
patients with COPD, exercise intolerance can result from one or a combination of the 
following: ventilatory limitation, impaired gas exchange, atrophy of peripheral muscles and/or 
peripheral muscle weakness and cardiac dysfunction [34]. In those with concomitant lung 
cancer, exercise capacity can be further reduced by the tumour(s) itself, which disrupts 
pulmonary mechanics and gas exchange, as well as a result of the lung cancer treatment, which 
can include lung resection, chemotherapy, radiotherapy and other options [35]. 
 
Exercise capacity of patients with COPD and/or lung cancer can be measured using either 
laboratory-based (such as maximal incremental cardiopulmonary exercise test [CPET]) or 
field-based exercise tests (e.g. six-minute walk test [6MWT] and incremental shuttle walk test 
[ISWT]). The importance of assessing exercise capacity in these populations is well-
established. In both patients with COPD and patients with lung cancer the peak rate of oxygen 
consumption (VO2peak) measured during a CPET has been shown to be a strong predictor of 
mortality [36, 37]. Furthermore, VO2peak measured before surgery is a strong predictor of 
postoperative pulmonary complications for patients undergoing lung resection for NSCLC [36] 
Of note, the performance during field-based walking tests have also demonstrated important 
prognostic value. A systematic review of 13 studies reported the association between six-
minute walk distance and mortality in patients with COPD [38]. In patients undergoing lung 
resection for NSCLC, poor performance in the 6MWT or the ISWT (i.e. < 400 m) before 
surgery is associated with an increased risk of postoperative pulmonary complications [39, 40].   
 
4. The role of exercise training/therapy   
 
Exercise training has been shown to improve exercise capacity in both patients with chronic 
lung diseases and patients with different types of cancer. In fact, exercise training, which is the 
cornerstone of pulmonary rehabilitation, is an integral component for management of patients 
with COPD. [41] When compared to COPD, research on exercise training in patients with lung 
cancer is on its infancy. However, recent studies have demonstrated its value across the whole 
lung cancer continuum, especially in patients with NSCLC [42-45].   
 
Pulmonary rehabilitation, including exercise training, should be offered to patients with stable 
COPD or following an exacerbation of their disease [34, 46]. A Cochrane review of 65 
randomised controlled trials (RCT’s) concluded that pulmonary rehabilitation significantly 
improves exercise capacity, health related quality of life (HRQoL), and symptom control in 
patients with COPD [47]. Of note, there was no difference between exercise training only and 
more complex pulmonary rehabilitation programmes [47]. Pulmonary rehabilitation following 
an exacerbation of COPD has been shown to reduce hospital readmissions [48]. In patients 
with early stage NSCLC, both preoperative and postoperative exercise training programmes 
have demonstrated to be effective at improving health outcomes [49, 43]. However, despite the 
growing evidence of the benefits of exercise training in this population, referral of such patients 
to exercise training programmes is still low [50]. A standard pulmonary rehabilitation exercise 
program runs between 6 to 8 weeks in duration. To minimise surgical delay, a modified 
exercise program of shorter duration with more frequent sessions is more appropriate for 
patients with lung cancer. Preoperative exercise training is mainly comprised of aerobic 
training and usually conducted whilst patients are waiting for surgery. In most studies to date, 
this timeframe ranged between 1 to 4 weeks [43]. In both cohort studies and a systematic review 
of randomized controlled trials (RCTs), short-term (2 to 4 weeks) intensive pre-operative 
pulmonary rehabilitation (or ‘pre-habilitation’) significantly improved baseline lung function, 
exercise capacity and symptoms in patients with lung cancer [51, 52, 43]. In addition, pre-
operative exercise training was associated with improved lung function recovery after surgery 
and reduced post-operative pulmonary complications (51, 73).   
 
A decline in exercise capacity and lung function, which is an important prognostic factor, is 
commonly observed following lung resection for NSCLC [53, 54, 36]. Postoperative exercise 
training programmes should be tailored to improve exercise capacity and health outcomes that 
may have been negatively affected by the lung resection. The usual duration and characteristics 
of the postoperative programme are derived from the COPD pulmonary rehabilitation 
literature. Programmes range between 8 to 12 weeks; sessions are performed 2 to 3 times/week 
and include both aerobic and resistance training. Postoperative exercise training has been 
shown to improve exercise capacity (VO2peak and six-minute walk distance),[49, 42, 44] total 
muscle mass[44] and HRQoL [44].  
In patients with advanced lung cancer exercise training programmes should aim to prevent 
deterioration in important clinical outcomes, control symptoms and maximise independence. 
This is an area of growing interest amongst researchers and clinicians, and there are several 
RCT’s being conducted to investigate effectiveness of exercise training in this population [55-
57]. To date, exercise training has been shown to be feasible and safe in patients with advanced 
lung cancer [58].     
 
5. Perioperative care for surgical candidates 
 
Surgical resection remains the treatment of choice for patients with early-stage NSCLC and 
co-existing COPD who have adequate physiologic reserve. Patients with COPD have higher 
post-operative morbidity and mortality following lung resection [59-62]. The degree of lung 
function impairment correlates with post-operative complications. Patients with lung cancer 
may have undiagnosed COPD or under-treated COPD. Timely assessment and management of 
COPD during perioperative period are important for optimisation of baseline lung function and 
fitness in order to minimise potential surgical morbidities. The evidence on short-term effects 
of these approaches for improving perioperative outcomes is limited. 
 
Long-acting bronchodilators, including long-acting muscarinic antagonists (LAMAs) and 
long-acting beta2-agonists (LABAs), are the mainstay therapy for long-term management of 
patients with COPD. Both agents have been shown to improve dyspnoea, lung function, 
exercise capacity and health-related quality of life, and to reduce exacerbation rate in patients 
with stable COPD [63, 64]. Perioperative commencement of long-acting bronchodilators, 
within 1 to 2 weeks prior to thoracic surgery significantly improved pre-operative lung function 
[65, 66]. Initiation of LAMAs or LABAs prior to surgery has also been shown to reduce post-
operative cardiorespiratory complications in patients with lung cancer [67, 68]. A randomized 
controlled trial by Suzuki et al demonstrated that the perioperative use of combined LAMA 
and LABA improved post-operative lung function and health-related quality of life in patients 
with COPD, particularly in those with moderate-to-severe disease [69]. Cardiovascular 
complications are common following thoracic surgery, particularly in those with COPD who 
are at high risk of cardiovascular events [61, 70]. Concerns have been raised that cardiovascular 
adverse events could be associated with the use of long-acting bronchodilators. Activation of 
beta2-agonists with LAMAs can precipitate arrhythmias, myocardial ischaemia and congestive 
heart failure. Muscarinic receptor antagonists have been associated with cardiovascular events 
in observational and clinical trials [67, 71]. However, increased incidence of post-operative 
cardiac complications, including arrhythmias, with the use of LABAs and LAMAs has not been 
reported in retrospective studies [67, 71].  
 
Although long-term use of inhaled corticosteroids has been shown to reduce exacerbations in 
patients with moderate-to-severe COPD, they have also been demonstrated to be associated 
with an increased risk of pneumonia [72-74] [75-78]. A retrospective study by Yamanashi et 
al revealed no association between perioperative use of inhaled corticosteroids and post-
operative respiratory complications [79]. Further, addition of inhaled corticosteroids to dual 
long-acting bronchodilators was associated with improved pre-operative lung function and 
reduced post-operative pulmonary complications in patients with COPD [66].    
 
To achieve the best outcomes for patients with lung cancer and COPD, optimising management 
of COPD should be integrated into routine care. Smoking cessation and short-term intensive 
preoperative pulmonary rehabilitation should be advocated. Dual bronchodilation with LAMA 
and LABA is the preferred therapy for improving patients’ baseline clinical status. Pre-
operative use of inhaled corticosteroids may have additional clinical benefits, particularly in 
those with moderate-severe COPD.  
 
6. Lung cancer radiotherapy  
 
Radiotherapy improves loco-regional disease control and survival in patients with lung cancer. 
However, radiation pneumonitis is a concerning side effect of thoracic radiotherapy as lungs 
are exquisitely sensitive to ionizing radiation. The incidence of radiation pneumonitis in lung 
cancer varies depending upon irradiation techniques and regimen. The reported incidence of 
clinically symptomatic radiation pneumonitis is up to 17% among patients undergoing radical 
radiotherapy [80, 81]. Patients with lung cancer are commonly being treated using newer 
irradiation techniques such as intensity-modulated radiotherapy (IMRT) and stereotactic body 
radiotherapy (SBRT) which provide more optimal radiation dose distribution and lower impact 
to normal tissue. In comparison to conventional radiotherapy, IMRT uses an involved-site 
technique to alter the intensity of radiation in different parts of a single radiation beam. On the 
other hand, SBRT administers higher doses of radiation over fewer fractions to an accurately 
delineated target. The use of IMRT has been shown to reduce rates of severe pneumonitis when 
compared to conventional radiotherapy (3.5% vs 7.9%) [82]. Clinically significant radiation 
pneumonitis develops in less than 10% of patients receiving SBRT for lung cancer [83, 84].  
 
Data are conflicting regarding the effect of COPD on the risk of radiation pneumonitis. 
Previous retrospective studies reported that COPD was associated with an increased incidence 
of radiation pneumonitis, including in those who received SBRT [85, 86].  However, in patients 
with lung cancer treated with radiotherapy, patients with severe COPD experienced milder 
radiation pneumonitis compared to those with normal lung function or milder COPD [87, 88]. 
It is possible that the lack of lung tissue associated with the presence of emphysema in patients 
with severe COPD reduces the potential for radiation-induced lung toxicity. Systemic 
glucocorticoids remain the mainstay therapy for patients with symptomatic radiation 
pneumonitis, with limited evidence suggesting that high-dose inhaled budesonide 800 μg twice 
daily may be a potential alternative therapeutic option [89].  
 
 
7. Systemic therapies 
 
While systemic chemotherapy is the standard of care for patients with advanced lung cancer, 
recent development of tyrosine kinase inhibitors (TKIs) and immunotherapy has revolutionised 
the management for these patients. Tyrosine kinase inhibitors are small molecule inhibitors of 
enzymes that regulate cellular growth factor signalling, while immunotherapies are monoclonal 
antibodies directed against immune checkpoint proteins to enhance endogenous immune 
responses against tumour cells [90]. Current approach of systemic therapies in lung cancer 
focuses on tailoring treatment choice according to tumour histology and molecular profiles. 
Compared to chemotherapy, TKIs and immunotherapies show promising results with sustained 
responses in selected patients. Although new systemic therapeutic agents are generally less 
toxic than systemic chemotherapy with favourable safety profiles, their unique mechanisms of 
action can result in a different array of side effects.    
 
Drug-related pneumonitis has been reported with the use of TKIs and immunotherapies. 
Systematic reviews found that the incidences for drug-related pneumonitis were 1.2% for 
epidermal growth factor receptor (EGFR) TKIs, 2.1% for anaplastic lymphoma kinase (ALK) 
TKIs and 1.3-3.6% for immunotherapies [91-93]. The mortality rates of drug-related 
pneumonitis were 22.8% for EGFR TKIs and 9% for ALK TKIs. Although COPD per se has 
not been identified as a risk factor for drug-induced pneumonitis, cigarette smoking is 
associated with an increased incidence of pneumonitis [94]. Interstitial lung disease, another 
risk factor for drug-induced pneumonitis, not uncommonly co-exists in patients with COPD 
[95]. In addition, long-term inhaled corticosteroids may increase the risk of Pneumocystis 
jiroveci pneumonia in patients with lung cancer and co-existing COPD who are treated with 
systemic therapies [96, 97]. This possible risk should be weighed against any potential 
improvement in lung function or symptoms achievable through the use of inhaled 
corticosteroids in individual patients, after considering other risk factors for opportunistic 
infection. It is important to monitor symptoms and lung function in patients with COPD and 
lung cancer who receive these agents in order to detect possible drug-related adverse effects 
early. 
 
Given that immunotherapies can modulate T-cell response via inhibition of immune 
checkpoints, they may be of potential therapeutic value for COPD. There are emerging data 
suggesting a potential role of dysregulated immune checkpoints leading to excessive T cell 
response in COPD [98]. Given the complex interplay of various inflammatory pathways in 
COPD, further investigations are required before translating this knowledge into clinical 
management.   
 
8. Mechanisms linking COPD and lung cancer   
The  major mechanisms linking COPD and lung cancer are likely related to common traits of 
both diseases, such as, oxidative stress, inflammation, genetic predisposition, epigenetics in 
lung cancer and COPD, extracellular vesicles (EVs), epithelial-mesenchymal transition (EMT), 
endothelial to mesenchymal transition (EndoMT), extracellular matrix (ECM) and 
angiogenesis. COPD has been shown to be a risk factor for lung cancer [99]; COPD patients 
are at five-fold higher risk to develop lung cancer as compared to those with normal pulmonary 
function [100]. Here, we discuss common mechanisms shared by both of these diseases.  
 
8.1 Oxidative stress  
 
Cigarette smoke contains more than 4000 different types of poisonous chemicals and is known 
to generate greater than 1000 oxidants per puff; oxidative stress can cause damage to the lung 
tissue by inducing cellular proteomic and transcriptomic changes. Reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) are among the more potent molecular candidates 
that interact with vital cellular organelles such as mitochondria and endoplasmic reticulum to 
cause potentially devastating imbalances in cellular metabolism. 
 
In both COPD and lung cancer, there are substantial evidence that points to increased ROS and 
RNS activity causing systemic cellular breakdown as well as inducing irreversible DNA 
damage. ROS generated through cigarette smoke directly affects inflammatory cells, 
systematically reducing their ability to mount efficient immune response to infections as well 
as obliterating cancer cells. In smokers and COPD patients Morlá et al [101] observed that 
peripheral  lymphocytes had shorter telomere length compared to normal healthy subjects, thus 
leading to a shorter cellular lifespan. This has been attributed to ROS, which are known to 
accelerate the process of cellular aging. Similar studies by Ceyalan et al. [102] also identified 
that circulating leukocytes in this population had severely damaged DNA with a considerable 
increase in lipid peroxidation mutagen markers such as plasma malondialdehyde (MDA) and 
TBA-reactive substances (TBARS). Thus, decreasing life span and DNA damage in 
lymphocytes in smoker and COPD patients make them more susceptible to cancer, in part due 
to weakened immune response resulting in inability to remove transformed or mutated cells. 
This fits with our current findings, where we recently reported that early COPD is associated 
with decrease in key inflammatory cell populations and making patients more susceptible to 
respiratory infections as well [103-105, 77, 78].  
 
In lung cancer, elevated levels of ROS induce single or double-stranded DNA breaks and 
abnormal DNA crosslinking [106]. This would result in arrest or induction of unwarranted 
transcription, replication errors, and genomic instability, all of which could lead to cancer 
induction and spread. In fact, common toxic oxidative chemicals from smoking such as B(a)P 
diol epoxide (BPDE) cause irreversibly damage to the DNA by forming DNA adducts through 
covalent binding or oxidation. BPDE–DNA adducts formation, if left unrepaired by nucleotide 
excision repair mechanisms, can block the transcription of essential genes, leading to 
unwarranted cellular effects [107]. Genome-Wide Association Study (GWAS) studies have 
also revealed that suboptimal DNA repair capacity (DRC) as a major determinant for genetic 
susceptibility to lung cancer although there have been considerable inter-individual variation 
in DRC partly due to the variability in DNA repair genes [108]. 
 
ROS also induces cellular senescence via DNA damage, arrests cellular growth and alters their 
function. Senesced immune cells have activated protein complexes leading to a condition 
termed senescence-associated secretory phenotype (SASP) which produce phlogogenic 
substances such as IL-1, IL-6, and IL-8 [109]. The cytokines produced are potent attractors and 
activators of innate immune cells, which cause tissue damage by producing even more 
oxidizing molecules, released mainly to destroy pathogens which are not necessarily there 
[110]. In lung cancer, cytokines that are enhanced in SASP complex are also known to be a 
prognostic marker for NSCLC. Interestingly, among them IL-6 is known to initiate growth and 
spread of lung cancer in mouse models, and has been attributed to the IL-6/STAT3 pathways 
[111].   
 
The impact of ROS and their association to smoking and lung cancer and COPD are of 
paramount importance and further understanding the underlying mechanisms could possible 
provide new therapeutic opportunity for early interventions. 
 
8.2 Inflammation  
 
Airway inflammation is known to play a critical role in COPD and cancer [112]. Over many 
years, the literature has provided important insight into the increases of both innate and 
adaptive immune cells in both bronchoalveolar lavage (BAL) and sputum samples in COPD 
[113, 114]. However, evidence suggests substantial contradiction about the actual picture of 
the type of inflammation in the airway wall wherein hypo-cellularity or cellular 
dysfunctionality/abnormalities are observed [114]. 
 
In lung cancer, it remains to be deciphered whether there is casual role of inflammation in 
enhancing mutations in cancer. However, inflammatory factors can enhance the progressive 
capacity of cancer cells. For examples, increased activation of NF-κB activity results in lung 
inflammation and substantial pro-tumorigenic effect. The effector cell population that mediates 
tumorigenicity are macrophages, which could be recruited to the lungs because of the epithelial 
cell induced NF-κB activation [115]. A number of studies have reported increase in alveolar 
and luminal macrophages in normal lung function smokers and COPD current smokers when 
compared to non-smoker controls [116]. Further, sub-phenotyping the macrophages in these 
patients groups also revealed predominantly M2 macrophages, with increased expression of 
phagocytic receptor CD163/CD206 [117, 114]. This increase in M2 macrophages switch was 
identified to be promoted by pro- Th2/M2 cytokines such as IL-4, IL-10, IL-13, CCL22, and 
IL-6 among others [114]. Interestingly, in tumour microenvironment itself, tumour-associated 
macrophages (TAMs) were shown to be predominantly M2 as well, which suggest that 
polarization of macrophages observed in mild-moderate COPD patients could be pro-
tumorigenic [118]. A recent meta-analysis with over 2500 NSCLC patients [119], observed 
that M2 macrophages were indeed the dominant macrophage phenotype and specifically the 
increase in survival of NSCLC patients was attributed to the sub-type of macrophages that 
dominated the tumour microenvironment [119, 118]. They concluded that patients with larger 
numbers of M2 macrophages had lesser chances of survival than those with M1 macrophage 
phenotype. Other than macrophages, lymphocytes especially cytotoxic CD8+ T cells also form 
an important link in both COPD and lung cancer. Interestingly, CD8+ T cells are the dominant 
T cell phenotype in mild-moderate COPD patients over CD4 T cells and this dominance may 
be partly due to increased susceptibility of COPD patients to viral infections [113]. Recently, 
McKendry et al [120] provided evidence of increased expression of PD-1 in CD8+ T cells and 
the ligands PD-L1 on macrophages in ex-vivo samples from mild-moderate COPD patients. 
The interaction between PD-1 and its ligand PD-L1 induce cell cycle arrest resulting in T cell 
anergy. Further, external administration of influenza virus led to an increased propensity of 
dysfunctional CD8+ T cells, estimated by their decreased ability to degranulate [120]. Similar, 
increased expression of PD-1 on CD8+ T cells was found to be especially higher in peripheral 
blood of patients with NSCLC and their interaction with PD-L1 in the tumour milieu is now 
an established target for antibody based therapeutic interventions such as Pembrolizumab in 
advance stages of cancer [121, 122].  
 
These studies are suggestive indicators that orientation of immune cell expression patterns in 
lung cancer are observed quite early in smokers and COPD patients than previously thought 
and that detecting these changes could help to design more effective future diagnosis and 
therapies that can address this more efficiently. 
 
8.3 Role of extracellular vesicles (EVs) 
 
Extracellular vesicles (EVs) are small membranous vesicles that are secreted or shed by cells. 
EVs are categorized as exosomes, ectosomes, microvesicles, or apoptotic bodies defined by the 
size of the particle [123]. In humans, EVs can be detected in various body fluids, including 
blood, urine, saliva, breast milk, ascites, and cerebrospinal fluid among others. The size of EVs 
vary from 30-1000 nm, depending on the type of EV, such as exosomes are the smallest (30-
100 nm) and larger are apoptotic bodies that are up to 100 nm [124]. Exosomes can play a 
crucial role in both COPD and lung cancer. EVs in general, are known to actively regulate 
tumour microenvironment (TME) by altering the immune response or through modulating 
through epithelial transition, fibroblasts activation or regulating angiogenesis [125]. The 
changes to the TME could take place through selective transfer mechanisms and would ideally 
involve both proteins and nuclear materials such as RNA. For examples, McCready et al [126] 
observed that HSP90α, in tumour associated secretory exosomes increases invasiveness of 
cancer cells through the activation of plasmin and annexin-II. Interestingly, HSP90α protein is 
abundant in COPD patients and act as potent biomarkers along with HSP 27 and 70 [127]. 
HSP90 potentiates epithelial mesenchymal transition (EMT) in several forms of cancer [128] 
and this phenomenon is active in early stage COPD patients as well, pointing towards possible 
association. Similar to transfer of proteins, miRNA-containing exosomes can be a determining 
factor in both lung cancer and other chronic lung disease [129]. miRNAs are known to 
selectively inhibit or silence mRNA translational process, thus acting as an important cellular 
modulator. For example, miR-200 family of miRNA can actively inhibit TGF-β1 induced EMT 
activity in airway epithelial cells [130] and forms a double negative feedback loop with a family 
of EMT-inducing transcription factors ZEB [131]. Observation in both lung cancer and COPD 
suggest a significant reduction in cellular miR-200 and an increase in extracellular exosomal 
miR-200 [132, 133]. The decrease in exosomal miRNA suggest active cellular expulsion 
through exocytosis of this essential regulator, leading to an increase in epithelial cell plasticity 
and mobility. Although, recent studies have implicated EV in the pathophysiology of lung 
cancer, a connection to smoking could lead to the discovery of potential biomarkers and novel 
therapeutic interventions [134]. 
 
8.4 Extracellular matrix (ECM) and proteinases 
 
Extracellular matrix (ECM) has important roles in maintaining tissue functionality and stability 
and regulating cell activities. The ECM is organised in two main structural types: 1) basement 
membranes in epithelia and endothelia and 2) interstitial network of fibrous proteins, 
glycosaminoglycans and matricellular proteins that provides structural support for cell types in 
the lung and maintains three-dimensional appearance and biomechanical characteristics [135, 
136]. Key ECM proteins maintaining tissue integrity are for example elastin, collagens and 
specific proteoglycans. The ECM is also an important storage source for different growth 
factors and cytokines, which are crucial for cell differentiation and proliferation [137, 138]. 
One of the major producers and regulators of ECM are fibroblasts, they synthesise large 
amounts of matrix components, different growth factors and inflammatory mediators. 
Fibroblasts may thereby have important modulatory roles in autocrine and paracrine fashions 
in regulating ECM in different lung compartments, and in giving rise to pathological changes 
in the ECM of lung cancers, such as increased collagen expression, altered collagen cross-
linking and subsequent increase in tissue stiffness [136]. SCLC is encircled by an extensive 
stroma of ECM and tumorigenicity has been shown to be enhanced by SCLC cells binding to 
the ECM, creating a highly specific microenvironment [139]. Activated fibroblasts, known as 
cancer-associated fibroblasts (CAFs), play an essential role in tumour progression by 
substantially remodelling tumour ECM, suppressing immune response and releasing tumour 
growth-promoting factors [140]. Thus, the tumour ECM provides a specialised 
microenvironment, favouring proliferation and metastasis and inhibiting apoptosis of tumour 
cells. Encapsulating tumour stroma can confer resistance to chemotherapy [139]. In COPD, 
there are processes ongoing in parallel with excessive ECM being produced manifested as 
peribronchial fibrosis and degraded ECM in the alveoli resulting in emphysema [137]. 
Alterations in elastic fibres, fibronectin, collagens, tenascin-C and versican have been 
identified throughout all lung compartments in patients with moderate COPD [141] and there 
are pronounced alterations in proteoglycan synthesis from central and distally-derived lung 
fibroblasts from patients with severe COPD [142]. Importantly, distal lung fibroblasts from 
severe COPD patients appeared to have altered fibroblast function and defect repair 
mechanisms in the ECM structure of the collagen network assembly in response to the 
prostacyclin analogue iloprost, which may thereby affect emphysema progression [143].  
 
The homeostasis of ECM is tightly regulated by matrix metalloproteinases (MMPs) and 
specific tissue inhibitors of metalloproteinases (TIMPs) [144] [145]. These proteases target the 
ECM for degradation, which alter tissue architecture and cause the release of ECM derived 
chemoattractant signals known as matrikines, which can propagate inflammation [146]. 
MMPs, especially MMP-2 and MMP-9, are implicated in the degradation of ECM in basement 
membranes, which facilitate tumour invasion and metastasis. MMP-2 is expressed in both 
normal and tumour tissues, whereas MMP-9 mostly is induced during tissue remodelling [145]. 
In cancer, MMP-9 overexpression may contribute to stimulate tumor vascularisation and tumor 
cell proliferation [147]. An overproduction of MMPs in intratumoral stromal cells is associated 
with poor prognosis of NSCLC [145, 147]. Interestingly, the proteoglycan decorin, which is 
essential for collagen fibrillogenesis, interacts with MMPs and can act as a tumour suppressor 
by attenuating tumour growth, migration and angiogenesis [148]. In COPD, there is an 
imbalance between MMPs and TIMPs which causes an overproduction of MMPs. Increased 
MMP activity and neutrophil elastases (NE) correlates with COPD pathology and especially 
MMP-9 has a major role in the development of emphysema [149]. The degrading of ECM by 
MMPs may also increase the bioavailability of growth factors, cytokines and receptors stored 
in the ECM.  
 
8.5 Angiogenesis   
 
Smoking, a key factor in both COPD and lung cancer, results in hypoxia, which is an important 
driver of angiogenesis. Nicotine may increase hypoxia-inducible factor (HIF)-1 in NSCLC and 
promote tumour angiogenesis [150, 151]. Vascular endothelial growth factor (VEGF) is one of 
the most important factors promoting angiogenesis and vascular remodeling processes [152]. 
In cancer, tumour progression from a benign to a malignant stage is often related to an 
angiogenic switch – which involves triggering and development of a vascular network that is 
actively growing and infiltrative [153]. As tumors increase in size their microenvironment 
becomes hypoxic and HIF is activated, which induce expression of MMPs and VEGF, leading 
to progression and invasion. VEGF correlates with progression, metastasis and poorer 
prognosis [154]. Proteinases induce the release of growth factors such as TGF-B and VEGF, 
which play a pivotal role in tumorgenesis and metastasis of lung cancer. CAFs have well-
established pro-angiogenic functions in tumours and are together with other hypoxic cancer 
cells major sources of secreted VEGF-A, which initiates tumour angiogenesis through vascular 
endothelial growth factor receptor (VEGFR) 2, expressed on endothelial cells [155]. During 
hypoxic conditions, prostacyclin synthase expression was up-regulated in human lung 
fibroblasts promoting VEGF synthesis in tumours [156]. 
 
Pulmonary vascular remodeling is common in COPD [152] and comorbidities in 
cardiovascular disease have negative impacts on COPD prognosis [157]. In COPD, airflow 
obstructions in small airways and destruction of alveolar capillaries result in decreased oxygen 
transport and alveolar hypoxia. This causes an activation of HIF, which promotes angiogenesis 
via VEGF [158]. Interestingly, VEGF is synthesised in high amounts by distally derived lung 
fibroblasts and induced by both prostacyclin and TGF-B. The synthesised VEGF acted in an 
autocrine fashion by increasing ECM synthesis, migration and proliferation of human lung 
fibroblasts [159]. However, in this study there were not any significant differences in 
synthesised VEGF levels between fibroblasts from non-smoking control subjects and those 
from patients with severe COPD. In line with these findings, expression of VEGF in pulmonary 
arteries did not differ between patients with severe COPD with emphysema and non-smoking 
control subjects, whereas patients with mild-moderate COPD showed an increased expression 
of VEGF [160]. COPD patients with chronic bronchitis had increased levels of VEGF in 
sputum in contrast to COPD patients with more emphysema that showed lower levels of VEGF 
[161]. Patients with acute exacerbations presented high levels of VEGF in the circulation 
compared to stable COPD patients and healthy individuals [162]. Increased VEGF expression 
is associated with bronchial angiogenesis that inversely correlated with lung function in COPD 
patients [163, 164]. In contrast, a decreased expression of VEGFR2 in parenchymal regions in 
severe COPD patients correlated with increased endothelial cell death [165]. Inhibition of 
VEGFR2 in an animal model resulted in emphysematous lung structure and cell apoptosis 
[166]. Interestingly, VEGF may act both as a promoter of endothelial cell function and a 
negative regulator of vascular smooth muscle cells (VSMCs) and vessel maturation in 
combination with platelet derived growth factor [167], highlighting the complex role of VEGF 
in vascular remodelling. Altogether, VEGF may have different roles depending on disease 
progression and disease severity. VEGF has the ability to bind to multiple proteins and 
proteoglycans present in the ECM [168, 169]. The proteoglycan biglycan is important for 
migration of cells [170] and may up regulate VEGF expression [171]. Endothelial cells that 
form vasculature play an important role in providing nutrients and oxygen to the tumour. We 
have previously reported the VEGF and TGF-β1 positive vessels and vessels in general 
increase in the reticular basement membrane (Rbm) of smokers and COPD patients but also 
seen encroaching into the epithelium [172-176]. It is quite possible that these two growth 
factors actively promote neoangiogenesis of the Rbm and epithelium itself supporting 
formation of a pro-cancer stroma with associated active epithelial mesenchymal transition 
(EMT) [173, 177]. In a separate study, we also reported effects on inhaled fluticasone 
propionate on vascular remodelling in COPD patients [177]. In this study, we observed that 
lamina propria vascularity returned to normality after the steroid treatment but the Rbm vessels 
did not decrease significantly after the 6 months of treatment. This also suggested that may be 
for complete depletion of Rbm vessels 6 months of corticosteroid therapy is inadequate, and 
angiogenic sustainability might be the reason for continues cancer growth in smokers and 
COPD patients [178]. We believe these are important clinical observations and warrants further 
investigations.  
 
In NSCLC the degree of tumour associated angiogenesis correlates with disease progression 
and predicts unfavourable survival outcome. High vascularity at tumour periphery has been 
correlated with tumour progression [179]. Perlecan is a major ECM protein located in 
pulmonary vessels, essential for the structure of vascular basement membranes [168, 142] and 
a crucial co-factor for VEGF binding and storage of VEGF [168]. A study on endothelial cell 
function showed that interaction between perlecan and VEGF-A promotes VEGFR2 signalling 
[180]. Down regulation of perlecan caused reduced angiogenesis in vivo [181]. Interestingly, 
perlecan and biglycan synthesis are reduced in fibroblasts from severe COPD patients [142]. 
Furthermore, endothelial-derived angiocrine signals were shown to induce regenerative lung 
alveolarization. Activation of VEGF2 and FGFR1 in pulmonary capillary endothelial cells 
induced MMP14 expression that unmasked EGF receptor ligands to enhance alveologenesis 
[182]. Perlecan, from endothelial cells in a paracrine way blocked proliferation and 
invasiveness of lung cancer by impacting pro-inflammatory pathways [183].  
 
Cyclooxygenase-2 (COX-2) is expressed in many tumours, especially adenocarcinoma, and 
associated with carcinogenesis and tumour resistance to anti-cancer drugs. COX-2 and 
prostaglandins (PGs) may thereby play a role in the pathogenesis of lung cancer via effects on 
angiogenesis, cell proliferation and apoptosis [184]. EGF-induced angiogenesis via the COX-
2 pathway involves p38 and JNK kinase activation pathways in endothelial cells [185]. COX-
2 is increased in the distal lung of COPD patients and increased in sputum of smokers together 
with MMP-2, which correlated with severity of airflow limitations in stable COPD patients 
[186]. COX-2 is also constitutively expressed in different lung cancers including NSCLC [184, 
187]. COX-2 via mPGES-1 and PGE2 receptor EP1 promote cancer growth in a chronic 
inflammatory environment [188]. Activation of PPAR-receptors by nicotine also induces 
expression of  PGE2 receptor EP4 through PI3-K signals and increased human lung carcinoma 
cell proliferation in NSCLC [189]. Interestingly, matrix stiffening and fibrosis appear to be 
linked through COX-2 suppression and reduced PGE2 levels in an autocrine feedback loop 
[190]. Preclinical and clinical studies have shown that COX-2 inhibitor has some efficacy for 
NSCLC [191], however further studies are warranted.  
 
8.6 Genetic predisposition 
 
A role for familial or genetic susceptibility has been suggested in both COPD and lung cancer. 
Genome-wide association studies (GWASs) have identified the same risk loci on chromosome 
15q that map to CHRNA3 and CHRNA5 – both of which are nicotinic acetyl-choline receptors 
that are associated with nicotine dependence and cigarette smoke consumption [192, 193]. The 
linkage of COPD, lung cancer and peripheral vascular disease, with these genes point out their 
possible role – surrogates for tobacco exposure [192]. Single nucleotide polymorphisms 
(SNPs) of other genes such as FAM13A (at 4q24) that encode for a RhoGTPase-activating 
protein binding domain have been associated with both COPD and lung cancer [193]. Although 
its functional contribution to lung cancer and/or COPD remains yet to be elucidated, the 
involvement of Rho GTPases in pulmonary endothelial barrier in lung suggests a potential 
mode of involvement for FAM13A [194]. 
 
8.7 Epigenetics in lung cancer and COPD 
 
Besides genetic susceptibility, epigenetic factors such as DNA methylation and covalent 
histone modifications have been reported to be important in developing COPD and lung cancer. 
A common methylation mark between COPD and lung cancer is that of CDKN2A that encodes 
for tumor suppressors p16 (INK4A) and p14 (ARF) [192], an observation consistent with both 
COPD and lung cancer viewed as ageing diseases [195]. Similarly, DNA methylation of 2 
genes CCDC37 and MAP1B was observed in COPD and lung cancer patients, with the greatest 
degree of methylation observed in patients with both diseases[195]. In cancer patients with 
COPD, immune genes expressed either by tumor cells or by tumor-infiltrating immune cells 
were highly methylated as compared to patients without COPD [196]. Thus, COPD may 
epigenetically alter the immune repertoire. 
 
8.8 Epithelial-Mesenchymal Transition (EMT) 
 
Epithelial-Mesenchymal Transition (EMT) is a biological process by which epithelial cells lose 
cell-cell adhesion and gain mesenchymal traits of migration, invasion, and producing 
components of extracellular matrix (ECM). EMT is a manifestation of airway basal 
reprogramming in smokers and COPD [197]. EMT need not be a binary process, rather cells 
can display a spectrum of phenotypes ranging from fully epithelial to fully mesenchymal [198-
200]. Hallmarks of EMT have been observed in airways of COPD patients and smokers, and 
NSCLC cells can attain partial EMT – i.e. a hybrid epithelial/mesenchymal (E/M) phenotype 
– or a complete EMT phenotype [200]. Thus, EMT has been proposed as a potential link 
between COPD and lung cancer.  
 
We have previously reported that EMT is an active process in both small and large airways of 
COPD patients [201-206]. EMT associated with organ fibrosis is deprived of angiogenesis, 
termed as Type-2 EMT and when it leads to the formation of pro-cancer stroma, it is termed as 
Type-III EMT, which is strongly associated with neo-angiogenesis [207, 99, 208]. We have 
shown that Type-2 EMT is active in small airways leading to small airway fibrosis/obliteration 
and Type-3 EMT is active in large airways, where cancer formation in quite common, 
especially squamous cell carcinomas [209, 210]. We also reported that inhaled fluticasone 
propionate has the potential to ameliorate airway EMT in COPD patients, suggesting EMT as 
a novel therapeutic target in this condition [173, 211, 212]. EMT may be the mechanism 
through which ICS provide protection against lung cancer in COPD, statins might have similar 
effects but more work is needed [178].  
 
Furthermore, EMT in COPD may be activated by interactions among epithelial cells and 
fibroblasts [213], reminiscent of non-cell autonomous regulation of EMT in lung cancer [214]. 
A recent report showed that acute cigarette smoke and associated infections, together plays an 
important role in driving complete EMT; thus an extra insult, such as an infections leads to 
more exaggerated form of EMT leading to chronically remodelled airways as observed during 
COPD [215]. SLUG and ZEB1 – transcription factors often associated with a partial EMT[213, 
216] – were activated in COPD bronchial epithelial cells, potentially enabling cell survival 
[217]. We also recently reported increased expressions of β-catenin, Twist and Snail in airways 
of smokers and COPD [206]. These transcriptional regulators of EMT correlated with markers 
of EMT and were associated with decrease in lung function in both smokers and COPD [206]. 
A partial EMT phenotype can be maintained by adenosine receptor A2BAR that can activate 
both EMT-inducing (ERK/MAPK) and EMT-inhibiting (cAMP/PKA) pathways[218], similar 
to the transcription factor NP63α that can both activate and inhibit ZEB1[219, 220]. 
Intriguingly, a hybrid E/M phenotype has been identified to possess enriched stem-like abilities 
as well as resistance to epidermal growth factor receptor inhibitor erlotinib [221]. The emerging 
notion about the highly aggressive behaviour of a hybrid E/M phenotype in cancer [222, 223] 
[224] argues for a potential role of a partial EMT in driving COPD, in addition to complete 
EMT.  
 
8.9 Endothelial-to-mesenchymal transition (EndoMT)  
 
Similar to epithelial plasticity in EMT, endothelial cells can also lose markers such as vascular 
endothelial cadherin (VE-cadherin) and can attain motile phenotype and express fibroblast 
associated markers such as vimentin, type I collagen, and α-smooth muscle actin (SMA). 
EndoMT is a critical process during embryogenesis, and especially play an important role in 
embryonic cardiac development [225]. However, when challenged by persistent damage and 
inflammation during pathological conditions, EndoMT get initiated and can contribute to  
organ fibrosis [226] and  promote cancer conditions as well [227-229, 226, 230]. Similar to 
EMT, EndoMT can also be a non-binary process, with cells apparently co-expressing both 
endothelial and mesenchymal markers, suggesting a dual role in disease manifestation [231]. 
EndoMT like EMT may be active in both COPD [232] [233] and lung cancer [234, 235]. In 
cancer, it is suggested that activated myofibroblasts and cancer associated fibroblasts (CAFs) 
produced by EndoMT can facilitate tumour growth and cancer progression. This also fits in 
with the underlying cancer pathology wherein tumours are heavily associated with increased 
angiogenesis. Thus, it is very much possible that endothelial cells are contributing to the pool 
of CAFs [227, 236, 230]. EndoMT can also initiate the formation of pro-cancer stroma quite 
similar to Type-3 EMT, so again it has the potential to initiate cancer and at the same time 
could help the tumour to thrive [230].  
 
Others and we have reported vascular remodelling in COPD, main structural changes involve 
intimal and medial thickening, leading to reduction of lumen diameter and muscularization of 
arterioles [237]. The other changes involve hypo-vascular lamina propria and hyper-vascular 
Rbm in large airways of smokers and COPD [238-240, 176, 241].  Both loss of vessels and 
vascular remodelling give rise to pulmonary hypertension in COPD [237, 242]. Interestingly, 
these vascular remodelling changes are also observed in early COPD and in normal lung 
function current smokers [237, 243, 158, 238-240, 176]. Increased expression of FSP-1 has 
been reported in occulated arteries and small vessels [243]. Abnormal deposition of pulmonary 
smooth like cells has been considered as the key pathological feature of arterial remodelling 
[244]. These cells lead to increased production of ECM proteins, with deposition of collagen 
and elastin proteins contributing to narrowing of arterial lumen hence pulmonary hypertension. 
But the origin of these smooth muscle like cells and the underlying mechanisms involved in 
vascular remodelling are poorly understood [244]. It is quite possible again EndoMT is the 
process which actively contributing to this pathology.  
 
EndoMT has been suggested to be involved in angiogenesis, where, during angiogenic 
sprouting, endothelial cells may compromise their basement membrane and migrate together 
as a ‘train’ of cells, indicating a partial EndoMT phenotype [231]. Similar collective migration 
has been observed in cells that are maintained in a partial EMT phenotype by molecular brakes 
such as OVOL2 or GRHL2 that can prevent a complete EMT [245-247][26–28]. Similar 
‘phenotypic stability factors’ for a partial EndoMT state remain to be identified. Computational 
approaches to calculate the rates and trajectories of EndoMT can be valuable in better 
characterizing the dynamics and phenotypic spectrum of EndoMT [248]. Recent studies have 
highlighted that ‘molecular EMT’ and ‘morphological EMT’ need not always occur 
simultaneously, i.e. cells expressing markers of EMT need not always migrate/invade, and cells 
that can invade/migrate need not show molecular markers of EMT[249, 250]. Similar criteria 
can be used to distinguish between ‘molecular EndoMT’ and ‘morphological EndoMT’. Thus, 
further investigations into the functional and morphological aspects of EndoMT shall yield 
better insights into the contribution of EndoMT in COPD and cancer progression. 
 
9. Insights from mouse models of COPD 
 
Animal models of CS-induced disease have been developed and have used guinea pigs, rats 
and mice [251, 252]. Mice are the most popular because of cost, ease of housing, and the 
availability of a plethora of molecular and immunological reagents and genetically modified 
strains [252-254]. Mouse models can be used to assess the impact of short-term CS exposure 
(1 day to 4 weeks) or the mechanisms involved in the development of COPD (up to 6 months). 
Many of the characteristic features of human COPD, such as chronic lung inflammation, 
pulmonary hypertension, airway remodelling, emphysema, and impaired lung function, can be 
generated in CS exposed mice [255-258, 252-254, 259-264]. The effects of CS also predispose 
to epithelial to mesenchymal transition (EMT) that contributes to the progression lung cancer 
[209, 265].  
 
In one model, mice were exposed to side-stream CS for 36 weeks that induced various 
hallmarks of human COPD, including increased airway resistance and respiratory system 
elastance [266]. However, this is a long model and shorter models that have the hallmark 
features of disease enable rapid progression of research, our understanding of COPD 
pathogenesis and aid in development of new treatments. Recently we developed a short-term 
mouse model of CS-induced experimental COPD, using nose-only exposure that develops the 
major features of the human disease in 8 weeks [252, 267, 253, 259]. Mice are exposed to the 
smoke of 12 cigarettes for 75 minutes, twice per day for 5 days per week [268]. The CS consists 
of normal air interspersed with puffs of CS and is representative of a pack-a-day smoker. This 
regimen results in acute and chronic airway and parenchymal inflammation, goblet cell 
metaplasia, airway remodelling, emphysema and impaired lung function [252, 259, 267, 253, 
254]. Like in humans, features are not suppressed by corticosteroid treatment and do not 
resolve over time, mice with experimental COPD are more susceptible to viral (influenza) and 
bacterial (Streptococcus pneumoniae) infections, and have systemic involvement with skeletal 
muscle loss, and effects on the gut and reproductive tract [269, 270, 252, 263].  
 
Current treatments for COPD such as corticosteroids and bronchodilators are poorly effective 
at inhibiting chronic inflammation, and do not reverse pathology. Thus, it is clear that there is 
an urgent need to develop new therapies to prevent the initiation and the progression of COPD, 
and an effective option is through the use of animal models that accurately reflect the 
physiopathology of the disease. Indeed, many potential future COPD therapeutics currently in 
clinical development, such as inhibitors of inflammatory mediators, oxidative stress, kinases, 
phosphodiesterases (PDE) and proteinases, were originally identified in studies using animal 
models. 
 
Various inhibitors of inflammatory mediators are being developed and tested for the treatment 
of COPD. Inhibitors of TRAIL, leukotriene B4 (LTB4), TNF-α, IL-1, IL-8, and epidermal 
growth factor have shown strong beneficial effects when used in animal models, however the 
translation into the clinic has been slow [271]. Studies exposing TNF-α receptor deficient mice 
to CS resulted in reduced inflammatory cells in lavage fluid and attenuated alveolar 
enlargement compared to wild-type mice [272]. These findings were supported by another 
knockout mouse study where both TNF-α receptors were shown to contribute to the 
pathogenesis of murine COPD, with TNF-α receptor-2 being the most active in the 
development of systemic weight loss, inflammation and emphysema [273]. However, as 
occurred with asthma, where mouse studies were not interpreted properly or transferred 
effectively into clinical studies, it is likely that selected groups or phenotypes of patients may 
respond better to specific treatments [274].  
 
Anti-oxidants, particularly those that target specific processes in COPD have shown some 
promise. Resveratrol and the antioxidant enzyme Gpx-1 have been shown to protect against 
lung inflammation and CS-induced emphysema in mice, and a Gpx mimetic also reduced lung 
inflammation when administered both prophylactically and therapeutically [275, 276]. 
Resveratrol is a plant originated polyphenol that suppresses lung inflammation through 
upregulating MyD88s which is a negative regulator of inflammation [276].  
 
Studies of animal models of CS-induced airway inflammation support the potential therapeutic 
use of kinase inhibitors, such as those that inhibit p38 mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K), in COPD [277]. MAPKs plays key roles in chronic 
inflammation [278], and the p38 MAPK pathway is activated by cellular stress and regulates 
the expression of a wide variety of inflammatory cytokines and remodeling factors including 
IL-8, TNF-α and MMPs [279]. PI3Ks play roles in controlling a wide variety of intracellular 
signaling pathways in asthma and COPD [280, 259]. Recent studies suggest that numerous 
components of the PI3K pathway contribute to the expression and activation of inflammatory 
mediators, inflammatory cell recruitment, immune cell function and airway remodeling as well 
as corticosteroid insensitivity in chronic inflammatory respiratory diseases such as asthma [281, 
280, 259]. We recently discovered that PI3K also plays a pivotal role in the pathogenesis of 
COPD as it’s activity is increased and it is utilised by influenza viruses during infection and it 
suppresses anti-viral responses [282, 259].  
 
The PDE4 inhibitor roflumilast, a licensed treatment for severe COPD, was originally 
identified as a potential therapeutic in acute and chronic murine models of CS-exposure [283]. 
PDE4 degrades the anti-inflammatory cyclic adenosine monophosphate and its inhibition in 
mice has been shown to have protective effects including reversing the loss of lung desmosine, 
a breakdown product of elastin, reducing neutrophil and macrophage influx, increasing the 
anti-inflammatory cytokine IL-10, and improving emphysema [283]. Other murine studies 
show that another PDE4 inhibitor rolipram had little effect on airway inflammation and 
remodeling or emphysema whereas a semicardazide-sensitive mono-amine oxidase inhibitor 
did [264]. 
 
Serine-, metallo- and cysteine proteinases are the primary proteinases implicated in the 
development of COPD [284]. In studies aimed at preventing the destruction of alveolar walls 
by proteolysis, and ultimately the development of emphysema, inhibitors of various proteinases 
have been trialed in animal models with varying levels of success. Emerging studies are also 
using mouse models to elucidate the roles of other new areas such as inflammasomes, 
microbiomes and the gut lung axis [285-289]. Collectively, the use of murine models of COPD 
and infectious exacerbations is valuable in furthering our understanding of the pathogenic 
aspects of the disease and can be used to identify novel therapeutic targets and develop and test 
new therapies [290]. The inherent heterogeneity of the disease can also be reproduced and 
studied in animal models using different combinations or doses of induction agents. 
 
 
10. Insights from mouse models of lung cancer  
 
Numerous different mouse models have been developed to study the etiology, transformation, 
invasion and metastasis of lung cancer. These models have been used to elucidate the 
mechanisms of cancer initiation, progression and metastasis, and to discover biomarkers, and 
testing preventions and treatments. Different types of mouse models of lung cancer have been 
developed with the vast majority using immunodeficient or genetically modified mice.  
 
Xenograft models are induced by injecting human lung cancer cells subcutaneously, 
orthotopically or systematically into immunocompromised mice. These models are mainly 
used to assess the efficacy of drugs before proceeding to clinical trials. Cell lines commonly 
used in xenograft mouse models are HCC4006, HCC827, H1975 and A549 for 
adenocarcinomas [291-293]; NCI-H1299 for carcinomas [294]; NCI-H460 for large cell 
carcinomas [295]; and NCI-H226 for squamous cell carcinomaa [296]. Another type is termed 
the patient derived xenograft (PDX) mouse model where surgically removed human primary 
tumour tissues are grafted into mice subcutaneously or orthotopically. These models are used 
to develop and test personalised therapies [297]. Although xenograft models are relatively poor 
in predicting clinical efficacy of drugs, these models have been successfully used for 
developing personalised therapy [298].  Circulating tumour cells (CTCs) derived explants 
(CDXs) of SCLC were used to develop personalised therapy using platinum and etoposide 
chemotherapy that showed similar drug response to patients [299]. Apart from this, xenografts 
models were also showed accuracy in testing the efficacy of a number of drugs like gefitinib, 
erlotinib and crizotinib which showed similar results in clinical trials [300-305]. 
 
Transgenic mouse models are generated by microinjecting modified DNA into zygotes, and 
are used to explore the functional activity of the gene of interest particularly their impact on 
the initiation, progression and metastasis of lung cancer [306]. A lung specific promoter is 
added to the coding region of the target gene in modified DNA to enable its expression only in 
the lung, and not in other organs or tissues [306]. A transgenic mouse model was developed to 
test the dependency of EGFR signalling in tumour development and progression. This model 
also showed that inhibiting EGFR through small molecular inhibitors (erlotinib or HKI-272) 
and humanized anti-hEGFR antibody (cetuximab) was effective in inducing tumor regression 
[307]. 
 
Syngeneic mouse models are generated by injecting immunologically compatible cancer cells 
into immunocompetent mice. The use of these models in  the study of lung cancer is rare and 
the only mouse model developed so far is the Lewis lung carcinoma model [308]. This model 
is valuable for investigating the tumour microenvironment and exploring the immune and 
toxicological responses of potential drugs. Spontaneous models are induced using oral, 
intraperitoneal or topical application of carcinogens to genetically susceptible but wild-type 
mouse strains like A/J and SWR. Carcinogens used are cigarette smoke, 4-methylnitrosamino-
3-pyridyl-1-butanone (NNK), benzo(a)pyrene for adenocarcinomas [309, 310], and N-nitroso-
tris-chloroethyl urea (NTCU) for squamous cell carcinomas [311]. Small cell lung cancer 
(SCLC) is induced through inactivation of both Rb and p53 genes. These models are valuable 
for exploring carcinogenesis, disease pathology, biomarker discovery, tumour 
microenvironment and roles of immune cells in cancer initiation development and progression, 
immune responses and the efficacy and toxicological of drug treatment [312].  
 
Carcinogens such as cigarette smoke and NNK, can be combined to induce adenomas and 
eventually after many months adenocarcinomas and the published models are long term 5-9 
months [313, 310, 314]. Initially, hyperplastic foci are seen in the bronchioles and alveoli that 
develop as adenomas and then progress to adenocarcinomas [315]. It is often difficult to 
distinguish adenomas, premalignant adenomas and malignant adenocarcinomas. 
Adenocarcinomas are mostly distinguished from other tumours based on certain characteristics 
like large pleiomorphic cells with vesicular nuclei, prominent nucleoli, undifferentiated 
cytoplasm and high mitotic index [316]. They are morphologically have both solid and 
papillary characteristics [317]. Tumours that develop in mice have low vascularization and 
metastatic potential [313]. Clara cells, alveolar type II cells, multipotent stem cells or derivative 
lineages of these cells are usually the cells of origin of tumours [317, 318]. The origin of 
papillary tumours is unclear, however, solid tumours usually originate from alveolar type II 
cells [317]. The histopathological and molecular characteristics of spontaneous mouse lung 
adenocarcinoma models are similar to the tumours that develop in humans [316].  
 
Squamous cell carcinoma (SCC) mouse models can be induced using NTCU administration 
and initially show premalignant lesions which progress to frank lung SSC that are similar to 
those that develop in humans [319]. SCLCs in mice are histologically similar and also 
metastasize to similar organs as in humans [320]. Neuroendocrine cells are believed to be the 
origin of SCLC [321].  
 
Although mice are genetically distinct and have some differences in lung physiology compared 
to humans, non-immunocompromised, non-genetically-modified spontaneous mouse models 
are more accurate in predicting clinical efficacy of investigating drugs [298]. NNK carcinogen- 
and CS-induced adenocarcinoma models in A/J mice were successfully used to show efficacy 
of different chemopreventive agents like isothiocyanates and their conjugates, glucocorticoids, 
green tea and non-steroidal anti-inflammatory drugs (NSAIDs) [322, 323]. Further 
characterisation of lung cancer mouse models and the development of novel models that 
accurately recapitulate the histological, immunological and molecular characteristics of human 
tumours are needed to advance our understanding of lung cancer and to discover more effective 
early diagnostics and treatment.      
 
 
11. Conclusions  
 
Currently, there is a lack of strong evidence to suggest that medical management for COPD 
should be modified in patients with concomitant lung cancer. Given both COPD and lung 
cancer are heterogeneous conditions, individualised treatment strategies are needed for patient 
management. Optimisation of care for COPD prior to, during and after definitive treatment for 
lung cancer should be part of the multidisciplinary management of patients with these dual 
pathologies. The use of long-acting bronchodilators and pulmonary rehabilitation are the 
mainstay management for these patients. Addition of inhaled corticosteroids is appropriate for 
patients with moderate-to-severe COPD and recurrent exacerbations. It becomes especially 
important given the fact that inhaled corticosteroid has potential to ameliorate EMT in COPD 
patients. EMT might be the process through which steroids protect lung cancer in COPD. 
However, steroids have been reserved for more severe form of COPD, so there is essential need 
for new therapeutics, which could be given in early disease state as 70% of lung cancer occurs 
in earlier stages of COPD. Therapeutic options available for patients with lung cancer and 
concomitant COPD improve with advances in radiotherapy such as IMRT and SABR, as well 
as systemic therapies such as TKI and immunotherapy. However, pneumonitis secondary to 
radiotherapy or systemic therapies is a potential significant side effect in patients with pre-
existing lung disease. At present, it is unknown whether COPD or its therapies may impact on 
the development or clinical course of therapy-related lung toxicity. Well-controlled clinical 
trials are needed to explore the efficacy of various strategies for reducing lung cancer risk in 
patients with COPD and improving clinical outcomes for patients with both diseases. There is 
essential need for development of pre-clinical animal models, which represents truly human 
disease. With increasing understanding of the molecular pathogenesis for lung cancer and 
COPD, new strategies using molecularly targeted therapies may be developed in future for 
prevention of lung cancer and treatment of COPD in this population.  
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Table 1: Observation studies of inhaled corticosteroids and risk of lung cancers in 
patients with COPD 
 
 Design (duration) Number of 
participants 
Type of ICS  Hazard ratio  
[95% CI] 
Parimon 
2007 
Retrospective 
cohort study 
(Median 3.8 years) 
ICS = 517 
No ICS = 
9957 
Triamcinolone, 
beclomethasone, 
flunisolide, 
fluticasone 
Adjusted: 
ICS < 1200μg = 1.3 (0.67-
1.90) 
ICS ≥ 1200μg = 0.39 
(0.16-0.96) 
Kiri 
2009 
Retrospective 
nested case-
control study  
(1989-2003 to 
June 2005) 
ICS = 127 
No ICS = 
1470 
Any ICS Overall = 0.64 (0.42-0.98) 
1-2 prescriptions/year = 
0.88 (0.51-1.52) 
3+ prescriptions/year  
= 0.51 (0.30-0.84)  
Liu 
2017 
Retrospective 
cohort study 
(Median 9.8 years) 
ICS = 1290 
No ICS = 
12396 
Fluticasone, 
Budesonide 
Overall = 0.70 (0.46-1.09) 
Cumulative ICS dose > 
39.48mg = 0.45 (0.21-
0.96) 
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